Press release
Lipodystrophy Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight
Discover Key Insights into the Lipodystrophy Market with DelveInsight's In-Depth Report @ Lipodystrophy Market Size [https://www.delveinsight.com/sample-request/lipodystrophy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Lipodystrophy Market Report
* In November 2024:- Amryt Pharma- An Open-label Extension of APG-20 Study to Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with Partial Lipodystrophy. This Phase 3 study is an Open Label Extension of the APG-20 Study To Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with Partial Lipodystrophy.
* According to DelveInsight's estimates for 2023, there were approximately 3,077 prevalent cases of rare disease lipodystrophy across the 7MM, with the United States accounting for 35% of these cases.
* In 2023, the EU4 countries and the UK together accounted for approximately 60% of the total lipodystrophy cases.
* In 2023, approximately 30% of lipodystrophy cases in the United States were classified as congenital generalized lipodystrophy. This condition involves near-total loss of body fat, resulting in prominent muscles, severe insulin resistance, early-onset diabetes, hypertriglyceridemia, and non-alcoholic fatty liver disease (NAFLD).
* In 2023, 93% of diagnosed lipodystrophy cases were partial lipodystrophy, predominantly affecting females. This is largely because familial partial lipodystrophy (FPL), a common type, is linked to genetic mutations in the LMNA or PPARG genes, which are more prevalent in women.
* The leading Lipodystrophy Companies such as Ionis Pharmaceuticals, Regeneron Pharmaceuticals, Boehringer Ingelheim , and others.
* Promising Lipodystrophy Therapies such as Metreleptin, Mibavademab, Baricitinib , and others.
Stay ahead in the Lipodystrophy Therapeutics Market with DelveInsight's Strategic Report @ Lipodystrophy Market Outlook [https://www.delveinsight.com/sample-request/lipodystrophy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Lipodystrophy Epidemiology
* Total cases of Lipodystrophy
* Lipodystrophy Subtype-specific Cases
* Lipodystrophy Gender-specific Cases
Download the report to understand which factors are driving Lipodystrophy epidemiology trends @ Lipodystrophy Prevalence [https://www.delveinsight.com/sample-request/lipodystrophy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Lipodystrophy Marketed Drugs
* MYALEPT (metreleptin): Amryt Pharma
Metreleptin mimics the physiological effects of leptin by binding to and activating the human leptin receptor, which belongs to the Class I cytokine family of receptors that signals through the JAK/STAT transduction pathway. Only the metabolic effects of metreleptin have been studied. No effects on the distribution of subcutaneous fat are expected.
The US Food and Drug Administration (FDA) approved MYALEPT (metreleptin) in 2014, Myalepta is indicated as an adjunct to diet as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy patients: with confirmed congenital generalized lipodystrophy or acquired generalized lipodystrophy in adults and children 2 years of age and above.
* EGRIFTA/EGRIFTA SV (tesamorelin): Thera Technologies
EGRIFTA/EGRIFTA SV is a growth hormone-releasing factor (GRF) analog indicated for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. EGRIFTA is used to reduce lipodystrophy caused by certain HIV medications. EGRIFTA is not a weight-loss medication and should not be used to treat obesity.
Lipodystrophy Emerging Drugs
* REGN4461: Regeneron Pharmaceuticals
Mibavademab (REGN 4461) is a leptin receptor (LEPR) agonist antibody developed by Regeneron pharmaceuticals to treat generalized lipodystrophy. The drug is currently in Phase II clinical trials conducted on patients with generalized lipodystrophy and familial partial lipodystrophy.
* Subcutaneous Metreleptin: Amryt Pharma
A 12-month randomized, multicenter, double-blind, placebo-controlled Phase III (METRE-PL) study to evaluate the safety and efficacy of daily subcutaneous metreleptin treatment in subjects with partial lipodystrophy.
Get In-Depth Knowledge on Lipodystrophy Market Trends and Forecasts with DelveInsight @ Lipodystrophy Treatment Market [https://www.delveinsight.com/sample-request/lipodystrophy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Lipodystrophy Market Outlook
The market for lipodystrophy treatments is evolving with a focus on both established and emerging therapies. In the United States, the market is dominated by key approved therapies like MYALEPT (metreleptin) and EGRIFTA/EGRIFTA SV (tesamorelin), with substantial revenue contributions from these treatments.
Lipodystrophy Treatment Market Landscape
Lipodystrophy treatment primarily focuses on managing the metabolic complications that result from abnormal fat distribution, such as insulin resistance, diabetes, and hypertriglyceridemia. The approach is personalized based on the type of lipodystrophy and the severity of symptoms. Metabolic management includes medications like metformin for insulin resistance and insulin therapy for diabetes, along with drugs such as fibrates or statins to lower triglyceride levels and reduce cardiovascular risk. Lifestyle modifications involving diet and exercise are also essential for controlling blood sugar levels and maintaining overall health.
Unlock Strategic Insights with DelveInsight's Comprehensive Lipodystrophy Market Report @ Lipodystrophy Market Drivers and Barriers [https://www.delveinsight.com/sample-request/lipodystrophy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Lipodystrophy Market Report
* Coverage- 7MM
* Lipodystrophy Companies- Ionis Pharmaceuticals, Regeneron Pharmaceuticals, Boehringer Ingelheim, and others.
* Lipodystrophy Therapies- Metreleptin, Mibavademab, Baricitinib, and others.
* Lipodystrophy Therapeutic Assessment: Lipodystrophy Current marketed and Lipodystrophy Emerging Therapies
* Lipodystrophy Market Dynamics: Lipodystrophy Market drivers and Lipodystrophy Market Barriers
Table of Content
1. Key Insights
2. Report Introduction
3. Lipodystrophy Market Overview at a Glance
4. Methodology
5. Executive Summary
6. Disease Background and Overview
7. Diagnosis
8. Treatment of Lipodystrophy
9. Diagnostic and Treatment Guidelines for Lipodystrophy
10. Conclusion
11. Epidemiology and Patient Population
12. Patient Journey
13. Approved Therapies
14. Emerging Therapies
15. Market Analysis
16. KOL Views
17. Market Barriers
18. Market Drivers
19. SWOT Analysis
20. Unmet Needs
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: yash bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=lipodystrophy-market-size-in-the-7mm-is-expected-to-grow-by-2034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/in-licensing-opportunity
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lipodystrophy Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight here
News-ID: 3747430 • Views: …
More Releases from ABNewswire
Author's Tranquility Press Announces the Inspiring Memoir How Rich Are You: Are …
Lucretia Ritsert's Journey Through Grief, Faith, and the Hidden Treasures of the Soul
Author's Tranquility Press is proud to spotlight How Rich Are You: Are You Listening [https://www.amazon.com/How-Rich-Are-You-Listening/dp/B0BWPKSCS5/ref=monarch_sidesheet_title], the moving memoir by Lucretia Ritsert that reminds us wealth is measured not in possessions, but in love, faith, and resilience.
Born out of personal loss, Ritsert's story carries readers from the silence of grief into the light of spiritual renewal. The passing of…
Andrew Leigh Honors Women Who Changed the Course Of History In Conversations Wit …
Andrew Leigh, co-founder of Maynard Leigh Associates, a leading UK training provider and much-published business author, has made a striking literary debut with his first non-fiction and non-business book, Conversations with Remarkable Women .
The book comprises imaginary conversations with twenty distinguished and high-achieving women from history. Leigh offers readers a fresh perspective on the lives and legacies of figures such as Catherine the Great, Mary Wollstonecraft, Harriet Tubman, Coco Chanel,…
McKay Law Continues Legacy of Excellence in East Texas Truck Accident Representa …
Record-Breaking Results Speak powerfully for clients
EAST TEXAS - October 27, 2025 - McKay Law, one of East Texas's most respected personal injury law firms, today reaffirmed its position as the region's premier choice for truck accident victims seeking maximum compensation and dedicated legal representation. With a proven track record of multi-million dollar verdicts, rapid-response investigation protocols, and an unwavering commitment to client success, McKay Law continues to set the standard…
Zero-Friction Automation: Anno Robot Offers 'Lifetime System Maintenance' and 90 …
The global retail sector is undergoing its most profound transformation in decades, driven by a confluence of rising labor costs, persistent staffing shortages, and a consumer demand for instant, 24/7 service. In this rapidly evolving landscape, the future of commerce is increasingly defined by automation. At the forefront of this shift is Anno Robot, a Shenzhen-based National High-Tech Enterprise that is not just selling robotic equipment but engineering a 'zero-friction'…
More Releases for Lipodystrophy
Lipodystrophy Market Detailed Industry Report Analysis 2025-2034
Introduction
Lipodystrophy is a rare and complex metabolic disorder characterized by the abnormal distribution or complete absence of body fat. Patients may present with severe insulin resistance, hypertriglyceridemia, fatty liver disease, and heightened cardiovascular risks, in addition to visible physical changes. The psychological and quality-of-life burden is substantial, making effective treatment critical.
Historically, management relied on symptomatic control through insulin sensitizers, lipid-lowering drugs, and lifestyle interventions. The approval of metreleptin (a recombinant…
Lipodystrophy Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Lipodystrophy Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Lipodystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Lipodystrophy Research. Learn more about our innovative pipeline…
HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of…
HIV Associated Lipodystrophy Syndrome Market 2017-2025 | TMR Research
Global HIV Associated Lipodystrophy Syndrome Market: Snapshot
HIV-associated lipodystrophy is a syndrome that are found in human immune-deficiency virus (HIV)-infected patients who are being administered with active antiretroviral medications for the treatment of HIV infection. Patients have lipohypertrophy, an abnormal central fat accumulation or lipoatrophy, localized loss of fat tissue, or a mixed clinical presentations representing both. The complex morphological signs associated with lipodystrophy syndrome inhibits our understanding of the etiology…
Lipodystrophy Therapeutics- Pipeline Analysis 2018 | Ionis Pharmaceuticals, Inc. …
Lipodystrophy is a rare medical condition which involves problems with fat production, usage, and storage. It is categorized into two types; congenital and acquired lipodystrophy.
Download the sample report @ https://www.pharmaproff.com/request-sample/1077
Congenital lipodystrophies include congenital generalized lipodystrophy, familial partial lipodystrophy, and marfanoid progeroid lipodystrophy syndrome; while acquired lipodystrophy includes acquired partial lipodystrophy, acquired generalized lipodystrophy, centrifugal abdominal lipodystrophy, lipoatrophia annularis, localized lipodystrophy and HIV-associated lipodystrophy.
Get the detailed analysis @ https://www.pharmaproff.com/report/lipodystrophy-therapeutics-pipeline-analysis
The…
HIV-associated Lipodystrophy Market Research Report 2017
Changes in body fat concentration, affecting people with HIV, is known as HIV-associated lipodystrophy. The exact causes of this condition is currently unknown, but research suggests that this disorder can occur either due to HIV infection or as a consequence of side effects associated with drugs used in HIV infection treatment, such as Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs), Protease Inhibitors (PIs), etc. The lipodystrophy condition is characterized by metabolic abnormalities,…
